Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.
Published By Datamonitor
|
15 Nov 2002 |
|
Expert View
|
Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?
Published By Datamonitor
|
22 Mar 2002 |
|
CommentWire
|
UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.
Published By Datamonitor
|
11 Jul 2002 |
|
CommentWire
|
Xanthus Life Sciences has begun dosing patients in a phase II trial of Symadex in recurrent colorectal cancer. While this is clearly a positive step in Symandex' development, the drug candidate still has phase III trials to contend with and, even if Symandex proves fit for launch here, Xanthus will need to find a marketing partner to help it achieve commercial success in the tough cancer market.
Published By Datamonitor
|
17 Jan 2006 |
|
CommentWire
|
Xanthus Pharmaceuticals has begun patient dosing in a Phase III trial of its drug Xanafide. Patients with secondary acute myeloid leukemia are poorly served by existing drug therapy; physicians are therefore likely to be enthusiastic about a drug which can improve treatment outcomes. At this stage of development, however, it is too early to forecast the chances of Xanthus's drug being successful.
Published By Datamonitor
|
10 Oct 2007 |
|
CommentWire
|
The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential.
Published By Datamonitor
|
10 Aug 2007 |
|
CommentWire
|
The 2002 halt of the WHI study using Wyeth's [WYE] Prempro triggered heavy losses to Premarin family sales. Now the remaining study, including Premarin itself, has also come to an abrupt end due an increased risk of stroke. After losing around $1 billion of the brand's annual revenue since 2002, this slide is now unlikely to slow.
Published By Datamonitor
|
05 Mar 2004 |
|
CommentWire
|
A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.
Published By Datamonitor
|
29 May 2003 |
|
CommentWire
|
Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.
Published By Datamonitor
|
29 Jul 2009 |
|
CommentWire
|
Wyeth has received an approvable letter from the FDA which confirms that bazedoxifene, to be marketed as Viviant, is likely to be indicated for the prevention of postmenopausal osteoporosis. This is the first step in what Datamonitor expects to be a successful and maintained brand lifecycle management strategy.
Published By Datamonitor
|
25 Apr 2007 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.